These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32945346)

  • 21. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody (134-mG
    Nanamiya R; Takei J; Ohishi T; Asano T; Tanaka T; Sano M; Nakamura T; Yanaka M; Handa S; Tateyama N; Harigae Y; Saito M; Suzuki H; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Feb; 41(1):1-7. PubMed ID: 35225663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
    Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
    Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and potential mechanisms of pyrotinib in targeting EGFR and HER2 in advanced oral squamous cell carcinoma.
    Zhou L; Le K; Chen Q; Wang H
    BMC Oral Health; 2024 Aug; 24(1):898. PubMed ID: 39107736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
    Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
    MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway.
    Yao S; Wang X; Li C; Zhao T; Jin H; Fang W
    Tumour Biol; 2016 Aug; 37(8):10247-56. PubMed ID: 26831667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody.
    Goto N; Suzuki H; Ohishi T; Harakawa A; Li G; Saito M; Takei J; Tanaka T; Asano T; Sano M; Kawada M; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):67-73. PubMed ID: 35377239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H
    Tanaka T; Suzuki H; Ohishi T; Kaneko MK; Kato Y
    Cancer Sci; 2024 Jan; 115(1):298-309. PubMed ID: 37942574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma.
    Ge H; Liu H; Fu Z; Sun Z
    J Int Med Res; 2012; 40(2):455-66. PubMed ID: 22613406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.
    Li G; Suzuki H; Ohishi T; Asano T; Tanaka T; Yanaka M; Nakamura T; Yoshikawa T; Kawada M; Kaneko MK; Kato Y
    Int J Mol Med; 2023 Feb; 51(2):. PubMed ID: 36660940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
    Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
    Kruser TJ; Armstrong EA; Ghia AJ; Huang S; Wheeler DL; Radinsky R; Freeman DJ; Harari PM
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):534-42. PubMed ID: 18793955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
    Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
    Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.
    Gonzales CB; De La Chapa JJ; Saikumar P; Singha PK; Dybdal-Hargreaves NF; Chavez J; Horning AM; Parra J; Kirma NB
    Oral Oncol; 2016 Aug; 59():12-19. PubMed ID: 27424178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of combining epidermal growth factor receptor inhibitors and cisplatin on proliferation and apoptosis of oral squamous cell carcinoma cells.
    Takaoka S; Iwase M; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S
    Int J Oncol; 2007 Jun; 30(6):1469-76. PubMed ID: 17487368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
    Dateoka S; Ohnishi Y; Kakudo K
    Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.